Illumina Raises Guidance as Director Sells $256M in Stock
Illumina reported Q2 revenue of $1.16B, up 9.5% year over year, and raised full-year revenue guidance to $4.60B–$4.64B, with U.S.-Canada clinical consumables growing more than 20%. Against that backdr
Illumina Lifts Guidance but Director Dumps $256M in Stock
NEW YORK, August 12 —
Illumina, Inc. (ILMN) has beaten consensus EPS estimates four consecutive quarters and just raised full-year revenue guidance, yet director Keith Meister has spent the entire 2026 rally liquidating: $256M across two concentrated bursts, first at $147, $165 in May, June, then at $197, $203 in the days immediately after the guidance raise.
- Q2 revenue $1.16B, up 9.5% YoY; non-GAAP EPS $1.31, up 10%; full-year guidance raised to $4.60B, $4.64B.
- U.S.-Canada clinical consumables grew more than 20% YoY; 83% of sequencing volumes now on NovaSeq X.
- Meister's largest single sale: 166,501 shares at $198.24 on August 4, five days after the guidance raise.
The Consumable Engine Is Working
Illumina sells the NovaSeq X high-throughput sequencer and the reagents, flow cells, and library prep kits consumed on every run to genomic research centers, hospitals, and pharmaceutical companies worldwide. Three years after launch, 83% of sequencing volumes have migrated to the platform; U.S.-Canada clinical consumables grew more than 20% year over year in Q2, per the Q2 2026 8-K. Illumina placed more than 95 new instruments in Q2, sustaining the installed base; management expects clinical conversion to reach 80%, 85% by year-end. Each new placement adds recurring consumable revenue, the driver behind the raised EPS guidance of $5.30, $5.40 and a key input for a DCF calculator run.
Two Valuations, One Boardroom
Director Keith Meister sold $256M in ILMN shares over 90 days with zero purchases, per SEC Form 4 filings, the only net seller among tracked insiders. The liquidation came in two bursts: May 28, June 1 at $147, $165 per share, then August 4-5 at $197, $203, the week after guidance was raised. His single largest trade was 166,501 shares at $198.24 on August 4. Illumina simultaneously repurchased its own shares in Q2 at an average of $129, roughly $70 below Meister's August prices. That gap implies two distinct valuations of the same company from the same boardroom.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ILMN | $28.8B | 31.3x | +90.7% |
| REGN | $81.8B | 13.2x | +41.9% |
| VRTX | $133.3B | 24.1x | +33.8% |
| BIIB | $30.5B | 12.4x | +50.8% |
| ISRG | $144.4B | 33.4x | -16.8% |
| CRSP | $5.2B | n/a | -5.7% |
Research Consumables Are the Canary
Research and applied consumables fell 7% year over year to $105M in Q2, and CEO Jacob Thaysen said customers "remain cautious as they navigate funding uncertainty," calling it too early to declare a recovery. Funding uncertainty hits academic and government labs before it touches clinical hospitals, and the Q2 dip arrived while the clinical business was running hot. Research consumables returning to year-over-year growth by Q3 earnings would settle the Meister-versus-management tension. If they stay negative while the director's exit continues, his read on duration looks more credible than the raised guidance. Run the free Illumina, Inc. deep-dive → for the current fundamentals.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What were Illumina's Q2 2026 earnings results?
Illumina reported Q2 revenue of $1.16B, up 9.5% year over year, with non-GAAP EPS of $1.31, up 10%. The company raised full-year revenue guidance to $4.60B, $4.64B and lifted EPS guidance to $5.30, $5.40.
How much did director Keith Meister sell in Illumina stock?
Meister sold $256M in Illumina shares over approximately 90 days with zero purchases, making him the sole net seller among tracked insiders. His largest single trade was 166,501 shares at $198.24 on August 4, five days after the guidance raise.
What is driving Illumina's consumable revenue growth?
U.S.-Canada clinical consumables grew more than 20% year over year in Q2, with 83% of sequencing volumes now running on the NovaSeq X platform. More than 95 new instruments were placed in Q2, and management expects clinical conversion to reach 80%, 85% by year-end, layering in recurring consumable revenue.
What is the risk flag in Illumina's research segment?
Research and applied consumables fell 7% year over year to $105M in Q2, with CEO Jacob Thaysen noting that customers remain cautious as they navigate funding uncertainty. A return to year-over-year growth in research consumables by Q3 would test whether management's raised guidance or Meister's continued exit better reflects the company's trajectory.
How did Illumina's buyback price compare to Meister's sell price?
Illumina repurchased its own shares in Q2 at an average of $129, while Meister sold at $197, $203 in August, a gap of roughly $70 per share. That divergence implies two distinct valuations of the same company from the same boardroom.
Illumina beat Q2 estimates and raised its full-year revenue and earnings guidance on July 30, sending shares up 5.7%. Days later, director Keith Meister sold shares in 14 separate transactions at prices near $200 — the second mass liquidation he has executed during the stock's 2026 rally.